Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed/Refractory Non-Hodgkin Lymphoma”

2,309 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 2,309 results

Testing effectiveness (Phase 2)UnknownNCT03245905
What this trial is testing

Study of Chidamide as a Single-agent Treatment for Patients With Relapse or Refractory B-NHL

Who this might be right for
Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma (NHL)
Sun Yat-sen University 100
Early research (Phase 1)Not Yet RecruitingNCT06712173
What this trial is testing

Linperlisib Combined With EZH2 Inhibitor in Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL)

Who this might be right for
Peripheral T Cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China 33
Testing effectiveness (Phase 2)UnknownNCT06149169
What this trial is testing

CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Large B-cell Lymphoma

Who this might be right for
Lymphoma, Non-HodgkinDiffuse Large B Cell Lymphoma
Shanghai Ming Ju Biotechnology Co., Ltd. 10
Testing effectiveness (Phase 2)Study completedNCT00967369
What this trial is testing

Combination Chemotherapy With or Without Bortezomib in Treating Patients With Classical Hodgkin Lymphoma That Has Returned or Does Not Respond to Prior Treatment.

Who this might be right for
Recurrent Classic Hodgkin LymphomaRefractory Classic Hodgkin Lymphoma
M.D. Anderson Cancer Center 20
Testing effectiveness (Phase 2)UnknownNCT02060656
What this trial is testing

Phase II Study Comparing LR-GEM to R-GEM-P in Second-line Treatment of Diffuse Large B-cell Lymphoma (LEGEND)

Who this might be right for
Diffuse Large B-Cell Lymphoma
Royal Marsden NHS Foundation Trust 92
Testing effectiveness (Phase 2)Study completedNCT01162551
What this trial is testing

Trial of Sirolimus and Methotrexate in Relapsed/Refractory Lymphoblastic Leukemia and Lymphoma

Who this might be right for
CancerLeukemiaLymphoma
Children's Hospital of Philadelphia 5
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07477366
What this trial is testing

Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma

Who this might be right for
Relapsed B-Cell Non-Hodgkin Lymphoma
ImmunityBio, Inc. 20
Large-scale testing (Phase 3)Active Not RecruitingNCT05409066
What this trial is testing

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma

Who this might be right for
Follicular Lymphoma (FL)
Genmab 549
Early research (Phase 1)Study completedNCT02568553
What this trial is testing

Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma

Who this might be right for
Recurrent Burkitt LymphomaRecurrent Diffuse Large B-Cell LymphomaRecurrent Grade 1 Follicular Lymphoma+23 more
National Cancer Institute (NCI) 35
Testing effectiveness (Phase 2)Ended earlyNCT02420795
What this trial is testing

Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Who this might be right for
Central Nervous System LymphomaGastric Mantle Cell LymphomaRecurrent Mantle Cell Lymphoma+4 more
M.D. Anderson Cancer Center 16
Testing effectiveness (Phase 2)Study completedNCT03192202
What this trial is testing

AFM13 in Relapsed/Refractory Cutaneous Lymphomas

Who this might be right for
Lymphoma, T-Cell, Cutaneous
Ahmed Sawas 18
Early research (Phase 1)UnknownNCT04004637
What this trial is testing

CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic Leukemia

Who this might be right for
T-lymphoblastic LymphomaNK/T Cell LymphomaAcute Lymphocytic Leukemia
PersonGen BioTherapeutics (Suzhou) Co., Ltd. 10
Early research (Phase 1)Active Not RecruitingNCT05784441
What this trial is testing

JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)

Who this might be right for
Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
Janssen Research & Development, LLC 21
Testing effectiveness (Phase 2)Study completedNCT05844956
What this trial is testing

DZD8586 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (TAI-SHAN1)

Who this might be right for
Lymphoma, Non-Hodgkin
Dizal Pharmaceuticals 17
Early research (Phase 1)WithdrawnNCT02875002
What this trial is testing

Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas

Who this might be right for
Relapsed and Refractory Aggressive B- and T-cell LymphomasLymphoma
Yale University
Testing effectiveness (Phase 2)Study completedNCT02600897
What this trial is testing

Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Who this might be right for
Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche 114
Testing effectiveness (Phase 2)Study completedNCT00156013
What this trial is testing

Clofarabine for Relapsed or Refractory T-Cell or B-Cell Non-Hodgkin Lymphoma (NHL)

Who this might be right for
Lymphoma, B-CellLymphoma, Non-Hodgkin
Oncology Specialists, S.C. 33
Early research (Phase 1)Looking for participantsNCT05780034
What this trial is testing

AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies

Who this might be right for
Relapsed/Refractory B-cell Malignancies
Accutar Biotechnology Inc 60
Early research (Phase 1)Study completedNCT01567709
What this trial is testing

Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma

Who this might be right for
Adult B Acute Lymphoblastic LeukemiaAdult T Acute Lymphoblastic LeukemiaAnaplastic Large Cell Lymphoma+32 more
National Cancer Institute (NCI) 34
Testing effectiveness (Phase 2)WithdrawnNCT04882163
What this trial is testing

Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma

Who this might be right for
Lymphoma, B-Cell
Celgene
Next Page